Comprehensive Financial Management LLC Purchases New Shares in Eikon Therapeutics, Inc. $EIKN

Comprehensive Financial Management LLC purchased a new stake in Eikon Therapeutics, Inc. (NASDAQ:EIKN) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 116,276 shares of the company’s stock, valued at approximately $1,517,000. Eikon Therapeutics comprises about 0.0% of Comprehensive Financial Management LLC’s holdings, making the stock its 26th biggest holding. Comprehensive Financial Management LLC owned approximately 0.21% of Eikon Therapeutics as of its most recent SEC filing.

Several other large investors have also bought and sold shares of EIKN. BlackRock Inc. grew its stake in shares of Eikon Therapeutics by 29.0% in the 2nd quarter. BlackRock Inc. now owns 4,281,425 shares of the company’s stock worth $55,873,000 after acquiring an additional 962,046 shares in the last quarter. Parkman Healthcare Partners LLC purchased a new stake in shares of Eikon Therapeutics in the second quarter valued at about $3,341,000. Bank of New York Mellon Corp bought a new position in shares of Eikon Therapeutics during the second quarter valued at about $624,000. The Manufacturers Life Insurance Company lifted its position in shares of Eikon Therapeutics by 23.5% during the second quarter. The Manufacturers Life Insurance Company now owns 35,357 shares of the company’s stock valued at $461,000 after purchasing an additional 6,734 shares in the last quarter. Finally, Deutsche Bank AG purchased a new position in Eikon Therapeutics during the second quarter worth about $281,000.

Eikon Therapeutics Trading Up 4.0%

Shares of Eikon Therapeutics stock opened at $10.88 on Wednesday. Eikon Therapeutics, Inc. has a 1 year low of $7.90 and a 1 year high of $17.40. The stock has a market cap of $589.37 million and a price-to-earnings ratio of -2.66. The company’s fifty day simple moving average is $10.59.

Eikon Therapeutics (NASDAQ:EIKN) last released its earnings results on Thursday, August 13th. The company reported ($1.63) EPS for the quarter, missing analysts’ consensus estimates of ($1.61) by ($0.02). As a group, equities analysts forecast that Eikon Therapeutics, Inc. will post -7.24 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

EIKN has been the subject of a number of recent analyst reports. Wedbush reduced their price objective on shares of Eikon Therapeutics from $5.00 to $4.00 and set an “underperform” rating for the company in a research report on Friday, August 14th. Cantor Fitzgerald reissued an “overweight” rating on shares of Eikon Therapeutics in a research report on Friday, August 21st. Finally, Weiss Ratings upgraded Eikon Therapeutics from a “sell (e-)” rating to a “sell (e)” rating in a research note on Monday, August 3rd. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $25.00.

About Eikon Therapeutics

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.